Literature DB >> 6459798

Chronic antigen-antibody-complex glomerulonephritis in mice.

M W Steward, M J Collins, C Stanley, M E Devey.   

Abstract

Daily injection of human serum albumin into mice genetically selected to produce low-affinity antibody to protein antigens resulted in a more severe antigen-antibody-complex-induced glomerulonephritis than in mice producing high-affinity antibody. The low-affinity mice had higher levels of circulating antigen-antibody complexes, greater impairment of renal function and reduced reticuloendothelial clearance of 125I-PVP compared to high-affinity mice. Electron microscopy of glomeruli revealed the presence of subepithelial electron-dense deposits in low-affinity mice and predominantly subendothelial-mesangial deposits in high-affinity mice which corresponded to the predominantly capillary staining in low-affinity mice and mesangial staining in high-affinity mice by immunofluorescence. Auto-radiography of electron-microscopy sections demonstrated the presence of antigen in the electron-dense deposits, indicating that these deposits indeed contained antigen-antigen complexes.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6459798      PMCID: PMC2041725     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  10 in total

1.  The genetic control of antibody affinity in mice.

Authors:  F E Katz; M W Steward
Journal:  Immunology       Date:  1975-09       Impact factor: 7.397

2.  Chronic immune complex disease in mice: the role of antibody affinity.

Authors:  M W Steward
Journal:  Clin Exp Immunol       Date:  1979-12       Impact factor: 4.330

3.  The genetic contribution of the NZB mouse to the renal disease of the NZB x NZW hybrid.

Authors:  J G Knight; D D Adams; H D Purves
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

4.  Saturation of the reticuloendothelial system with soluble immune complexes.

Authors:  A O Haakenstad; M Mannik
Journal:  J Immunol       Date:  1974-05       Impact factor: 5.422

5.  Antibody affinity and clearance function studies in high and low antibody affinity mice. The effect of protein deficiency.

Authors:  M C Reinhardt; M W Steward
Journal:  Immunology       Date:  1979-12       Impact factor: 7.397

Review 6.  The glomerular mesangium.

Authors:  A F Michael; W F Keane; L Raij; R L Vernier; S M Mauer
Journal:  Kidney Int       Date:  1980-02       Impact factor: 10.612

7.  In situ immune complex formation and glomerular injury.

Authors:  W G Couser; D J Salant
Journal:  Kidney Int       Date:  1980-01       Impact factor: 10.612

8.  Passive immune complex glomerulonephritis in mice: models for various lesions found in human disease. I. High avidity complexes and mesangiopathic glomerulonephritis.

Authors:  F G Germuth; E Rodriguez; C A Lorelle; E I Trump; L Milano; O Wise
Journal:  Lab Invest       Date:  1979-10       Impact factor: 5.662

9.  Measurement of antigen-antibody complexes in mouse sera by conglutinin, C1q and rheumatoid factor solid phase binding assays.

Authors:  M E Devey; J Taylor; M W Steward
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

10.  The induction of chronic antigen-antibody complex disease in selectively bred mice producing either high or low affinity antibody to protein antigens.

Authors:  M E Devey; M W Steward
Journal:  Immunology       Date:  1980-10       Impact factor: 7.397

  10 in total
  3 in total

1.  Antigen feeding modifies the course of antigen-induced immune complex disease.

Authors:  M E Devey; K Bleasdale
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

2.  Capillary-localized low-affinity antibody-antigen complexes act as a focus for the deposition of high-affinity complexes.

Authors:  K Moulder; M W Steward
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

3.  Effect of cyclosporin on immune complex deposition in murine glomerulonephritis.

Authors:  D G Quinn; J S Fennell; O Sheils; E F Gaffney; C F Feighery
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.